It’s an evolving exercise in high tech applied science….
Excerpt: “Producers are required to obtain potency data for THC and CBD, the two most common cannabinoids. It’s important for consumers to know THC and CBD levels because these will have a strong influence on the effects. For example, some medical patients may want a strain with a high CBD:THC ratio, while adult-use consumers may request the opposite.
Other cannabinoids and terpenes, can be tested for as well, although these measurements are typically not required by law.
In Washington state, a group of I-502 accredited laboratories are undergoing a ’round robin,’ measuring the potency of an unknown cannabis sample and comparing the results between laboratories. If proper testing practices are in place at each laboratory, reported potency data should be similar across the board.”
So another kick in the head to one argument (made by the UMA and other opponents, i.e., refuting the contention that we can’t provide patients with known, standardized doses of whole plant cannabis.
Because we can.
TRUCE additionally feels that sensible regulations designed to ensure that what patients receive has been assayed and inspected for safety, purity, insecticides, heavy metals, etc. should be part of all legal programs.
Medical cannabis made legally available to patients can be produced under conditions which will allow them to meet the same stringent standards as any other medicine approved for patients.
See full article – Cannabis Potency: How Does Lab Testing for THC and CBD Work? | Leafly